Table 1 Demographic data of the proposals reviewed within the past 5 years by our IRB
Non-approval | Approval | X2∕t | P | |
|---|---|---|---|---|
n = 56 | n = 159 | |||
Type | ||||
Expedited | 50 (89.3 %) | 125 (78.6 %) | 3.113 | 0.109 |
Full-board | 6 (10.7 %) | 34 (21.4 %) | ||
Vulnerable case | 18 (32.1 %) | 59 (37.1 %) | 1.154 | 0.338 |
Drug study | 8 (14.3 %) | 13 (8.2 %) | 1.754 | 0.196 |
Genetic study | 16 (28.6 %) | 38 (23.9 %) | 0.481 | 0.480 |
PI training | 3.996 | 0.262 | ||
6 h | 0 | 1 (0.63 %) | ||
> 6 h | 2 (3.6 %) | 13 (8.2 %) | ||
DOH | 50 (89.3 %) | 141 (88.7 %) | ||
CITI program | 4 (7.1 %) | 4 (2.5 %) | ||
Within organization | 49 (87.5 %) | 108 (67.9 %) | 8.565 | 0.014 |
Administration time (day) | 1. 27 ± 1.51 | 0. 78 ± 1.03 | 2.676 | 0.008 |
Revision frequency | 1. 82 ± 0.57 | 1. 40 ± 0.76 | 3.744 | 0.000 |
Total review time (day) | 47. 8 ± 50.5 | 31. 4 ± 24.1 | 3.203 | 0.002 |